The potential of PARP inhibitors in new cancer groups and in combination with other treatments

Bookmark and Share
Published: 18 Jun 2019
Views: 504
Dr Jennifer Litton - The University of Texas MD Anderson Cancer Center, Houston, USA

Dr Jennifer Litton talks to ecancer at the 2019 American Society of Clinical Oncology (ASCO) Annual Meeting about using PARP inhibitors in other tumour types, outside of ovarian and breast cancer, and in combination with other treatments.

She explains that combinations with PARP inhibitors are particularly exciting with immunotherapy highlighted as a promising combination option.

This programme has been supported by an unrestricted educational grant from Pfizer.